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ABSTRACT: 
Introduction: Gonadotropin-releasing hormone (GnRH) deficiency causes hypogonadotropic 
hypogonadism (HH), a rare genetic disorder that impairs sexual reproduction. HH can be due to 
defective GnRH-secreting neuron development or function and may be associated with other 
clinical signs in overlapping genetic syndromes. With most of the cases being idiopathic, genetics 
underlying HH is still largely unknown. 
Objective: To assess the contribution of mutated Semaphorin 3G (SEMA3G) in the onset of a 
syndromic form of HH, characterized by intellectual disability and facial dysmorphic features. 
Method: By combining homozygosity mapping with exome sequencing, we identified a novel 
variant in the SEMA3G gene. We then applied mouse as a model organism to examine SEMA3G 
expression and its functional requirement in vivo. Further, we applied homology modelling in silico 
and cell culture assays in vitro to validate the pathogenicity of the identified gene variant.  
Results: We found that (i) SEMA3G is expressed along the migratory route of GnRH neurons and in 
the developing pituitary, (ii) SEMA3G affects GnRH neuron development, but is redundant in the 
adult hypothalamic-pituitary-gonadal axis, and (iii) mutated SEMA3G alters binding properties in 
silico and in vitro to its PlexinA receptors and attenuates its effect on the migration of immortalized 
GnRH neurons. 
Conclusion: In silico, in vitro and in vivo models revealed that SEMA3G regulates GnRH neuron 
migration and that its mutation affecting receptor selectivity may be responsible for the HH-related 
defects. 
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INTRODUCTION  
Puberty onset and sexual reproduction are controlled in mammals by the hypothalamic-
pituitary-gonadal (HPG) axis, which is composed of Gonadotropin-releasing hormone (GnRH) 
neurons in the hypothalamus, gonadotropic cells in the anterior pituitary and sex-steroid producing 
cells in the gonads (1). The activation and maintenance of the HPG axis depend on the cyclic 
secretion of the decapeptide GnRH by GnRH neurons, which comprise a small number of cells 
scattered in a bi-lateral continuum between the olfactory bulbs (OB) and the hypothalamic medial 
preoptic area (MPOA) (2). GnRH deficiency impairs puberty and leads to infertility, causing a genetic 
disorder that is known as hypogonadotropic hypogonadism (HH), which is due to defective GnRH 
neuron development or function (3). For the majority of the patients affected by HH, the underlying 
genetic loci are unknown (4). Further, GnRH deficiency can be found in combination with other 
phenotypic features in genetic disorders associated to HH. These include CHARGE (CS), Prader-Willi 
(PWS) and Bardet-Biedl (BBS) syndromes, which are characterized by a spectrum of additional 
clinical traits such as eye and ear defects, craniofacial malformations, mental retardation, renal and 
heart anomalies (5–7). 
Here we have identified two brothers affected by an unusual syndrome that includes HH, facial 
dysmorphic features and developmental delay, born to consanguineous parents and sharing a large 
region of homozygosity on their genome. By combining homozygosity mapping (HZM) of their DNA 
with exome sequencing, bioinformatics, functional in vitro and in vivo studies, we identified a 
mutation in Semaphorin 3G (SEMA3G) and functionally studied its requirement in the GnRH neuron 
system.  
SEMA3G encodes a recently characterized (8) member of the class 3 secreted semaphorin 
subfamily. To date, other members of SEMA3s and their receptors/co-receptors have already been 
implicated in the development of the GnRH neuron system (9–11) and in the pathogenesis of HH 
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(10–16). Yet, the role of SEMA3G in the establishment of the neuroendocrine reproductive axis has 
not been investigated. Previous mouse work mainly revealed roles for SEMA3G in the patterning of 
the vascular system (17,18). Accordingly, Sema3g is expressed by endothelial cells and not by 
neurons or glial cells (19,20). However, endothelial  Sema3g  can regulate synaptic plasticity of 
neurons (19). Similar to other class 3 semaphorins, SEMA3G binds to both neuropilins (NRP1-2) 
(8,18,19) in complexes with plexin A4 (PLXNA4) (19) or D1 (PLXND1) (18).  
In this study, we found that Sema3g transcript is transiently expressed by endothelial cells 
associated with migrating GnRH neurons in the nose and that mice lacking Sema3g showed a 
defective migration of GnRH neurons during development. However, adult Sema3g-null mice did 
not phenocopy the reproductive defects observed in our patients. Thus, by studying in silico and in 
vitro the effects of SEMA3G mutation, we found that the mutation alters binding affinity and 
selectivity to its PLXNA co-receptors. In addition, mutated SEMA3G interferes with the binding and 
the signaling of SEMA3A ex vivo and in vitro. Further, the mutated SEMA3G is less effective in 
promoting proliferation, migration and AKT activation in an in vitro model of immortalized GnRH 
neurons.  
 
MATERIALS AND METHODS 
Human samples and DNA sequencing. Blood samples were collected from the family through Great 
Ormond Street Hospital’s NHS Trust. Genomic DNA was isolated by standard techniques at the UCL 
Genomics centre, and the samples were stored at -80°C until analysis. 
HZM was conducted by the UCL Genomics services. The Illumina microarray platform was used for 
the genotyping, following the Infinium HD Ultra Assay protocol (Rev B, 2010, Illumina Inc, San Diego, 
USA). Results were generated using the Illumina Genomestudio software, and copy number 
variation and loss of heterozygosity data was generated (cnvPartition v3.1.6, Illumina). The 
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minimum homozygous region size was 1Mb, with a minimum of 50 consecutive SNPs. Whole exome 
sequencing was conducted on the 2 patients and their unaffected siblings out of UCL. HZM and 
exome sequencing data were used simultaneously in patient 2 to identify the candidate 
gene/mutation lying within the homozygous regions.  
Sanger sequencing was performed to detect mutations in the affected patients and their family. 
Primers were designed using the online Primer3 software. The sequencing reaction was conducted 
using the BigDye Terminator V1.1 Cycle Sequencing kit (Applied BioSystems, Foster City, CA, USA). 
The sequences were compared to a reference sequence using the Sequencher® 5.3 software. In 
silico mutational analysis was performed to predict the effect of the mutation. 
Mouse strains/approvals. To obtain embryos of defined gestational stages, mice were mated in the 
evening, and the morning of vaginal plug formation was counted as E0.5. Genotyping of Sema3g 
wild-type or knock-out mice (in C57BL/6 background) was performed by polymerase chain reaction 
(PCR) (17). Wild-type (CD1 or C57BL/6) or knockout mice were housed in individually ventilated 
cages under pathogen-free conditions. Animals had free access to food and water and were kept in 
a 12h light-dark cycle. All procedures were performed in accordance with the European Community 
Council Directive 86/609/EEC for care and use of experimental animals; all the protocols were 
approved by local ethical and German home office guidelines, by the UK Animals (Scientific 
Procedures) Act 1986 as well as by the Italian Minister for Scientific Research and by the local Animal 
Care Committee.  
In situ hybridization. Paraformaldehyde (PFA)-fixed cryosections or paraffin-embedded sections 
from wild type C57BL/6 animals were incubated with digoxigenin (DIG)-labelled anti-sense 
riboprobes for mouse Gnrh (gift of Dr. Memi), Pit1, Pomc1, α-GSU (21), Sema3g. Oligonucleotides 
used to generate Sema3g probe were: Forward: CCTTCATCACAGTGGGGCAT: Reverse: 
GGTAATACGACTCACTATAGGGATAGGGTCCCCACTGATGCT. The T7 promoter is added at 5’ of 
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reverse primers. Specificity of this probe was tested using a sense probe (Suppl. Fig. 1). 
Hybridisation step was performed in hybridization buffer (50% formamide, 0.3M sodium chloride, 
20mM Tris HCl, 5mM EDTA, 10% Dextran sulphate, 1x Denhardt’s) overnight at 55-65°C depending 
on probe stringency. Sections were washed with a series of gradually decreasing saline sodium 
citrate (SSC) buffers and then incubated overnight with AP-conjugated anti-DIG antibody (1:1500; 
Roche). mRNA expression was revealed by colorimetric staining using 4-Nitro blue tetrazolium 
chloride solution and 5-Bromo-4-chloro-3-indolyl phosphate disodium salt (NBT/BCIP, Roche).  
Histochemical procedures. PFA-fixed cryosections (20 Pm thickness) or paraffin-embedded sections 
(5-10 Pm) were incubated for 1h at RT with PBS containing 10% normal goat serum and 0.1% 
TritonX-100. Cells were fixed for 15min with 4% PFA and then blocked for 30min with 5% normal 
goat serum and 0.1% TritonX-100. The following primary antibodies, whose specificity was tested in 
our or other previous works, were used for immunostainings: rabbit anti–peripherin (1:200; AB 1530 
EMD Millipore; (9,10)), rabbit anti-GnRH (1:400 for fluorescence and 1:1000 for peroxidase labelling; 
20075 Immunostar; (9,10,22)), rabbit anti-S100 (1:500; Z0311 Dako Omnis, Agilent; (23)), mouse 
anti-Tuj1 (1:500; MMS-435P-250 Covance; (23)), mouse anti-cMyc (1:200; MA1-980 Thermo Fisher 
Scientific; (10), rabbit anti-PHH3 (1:2000; 9701S Cell Signaling; (24), rabbit anti-caspase 3 (1:200; 
9661S Cell Signaling; (25)). Pituitary hormone-producing cells were labelled using the following 
primary antibodies on 5 Pm paraffin-embedded tissue sections: mouse anti-ACTH (1:1000, 10C-
CR1096M1 Fitzgerald), rabbit anti-PRL (AFP-425-10-91), -LH (AFP-C697071P), -TSH (AFP-1274789) 
and -GH (AFP-5641801) (1:500, NHPP, UCLA Medical Centre (26). BV were labelled either with 
biotinylated-isolectin B4 (IB4) (1:400; Vector Laboratories; (10)) followed by 488- or Cy3-conjugated 
streptavidin or with rabbit anti-CD31/Pecam (1:50; ab28364 Abcam; (27)) or rat anti-Endomucin 
(1:300; sc-65495 Santa Cruz; (28)). For testes analysis, testes were embedded in paraffin and 
sections of 8 Pm cut with a microtome. Sections were then stained with haematoxylin and eosin or 
immunolabelled with an anti-Sox9 antibody (1:1000; gift of Prof. Wegner; (29)) or with a rabbit anti-
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Cyp17a1 antibody (1:100; 14447-1-AP Proteintech; (30)). For immunofluorescence staining, 
secondary antibodies used included 488-conjugated goat anti-mouse IgG (1:400; Jackson 
Immunoresearch), Cy-3 or 488-conjugated goat anti-rabbit (1:400; Jackson Immunoresearch). 
Nuclei counterstained with DAPI (1:10000; Sigma-Aldrich). For immunoperoxidase labelling, 
cryostat or microtome sections were incubated with hydrogen peroxide to quench endogenous 
peroxidase activity followed by biotinylated goat anti-rabbit, goat anti-mouse or goat anti-rat 
antibody (1:400; Vector Laboratories) and then developed with the ABC kit (Vector Laboratories) 
and 3,3-diaminobenzidine (Sigma-Aldrich) as previously described (10). In some experiments, we 
performed ISH for Sema3g before immunostaining for GnRH, Tuj1, S100 or IB4 (31).  
Quantitative RT-PCR. RNA was collected from adult P80 testes of wild-type and Sema3g-null mice 
using Trizol-chloroform method. After extraction, 1 μg of RNA for each sample was retrotranscribed 
and cDNA obtained was used for quantitative (q) PCR analyses as previously described (32). The 
following primers were used for Sox9 and Cyp17a1 respectively (FW 5’-ACGCCTTCATGGTGTGG-3’, 
RV 5’-TCTCGCTCTCGTTCAGCAG-3’; FW 5’-CATCCCACACAAGGCTAACA-3’, RV 5’ 
CAGTGCCCAGAGATTGATGA-3’). Gapdh was used as housekeeping gene for the normalization of 
data and the mRNA relative expression was calculated using the mean of wild-type samples as 
reference. 
Homology modeling. Homology modeling of the interaction between human SEMA3G and human 
PLXNA1-4 was performed with the Molecular Operating Environment (MOE, 2015.10; Chemical 
Computing Group Inc.). In detail, four complexes of the human SEMA3G and human PLXNAs 
(SEMA3G::PLXNA1-4) were generated, using as templates the high-resolution mSema3a (PDB CODE 
1Q47.A) and mPlxna2 (PDB CODE 3OKY) structures, respectively, to model the single monomers, 
and the low-resolution mouse Sema3a, Plxna2, Nrp1 complex to guide their reciprocal 
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orientation/interactions (PDB CODE 4GZA, 7 Å resolution) (33). Amber10:EHT with the reaction field 
electrostatics treatment was used. 
Protein::protein molecular docking. Protein::protein molecular docking was carried out on human 
SEMA3G with human PLXNAs, producing 4 final complexes (SEMA3G::PLXNA1, SEMA3G::PLXNA2, 
SEMA3G::PLXNA3, SEMA3G::PLXNA4). The protein::protein docking procedure was validated by 
reproducing the Sema3a::Plxna2 crystallized complex, used as positive control. The residues of the 
interaction surfaces were manually selected on the different proteins used in the docking 
procedure: human SEMA3G (P96-N117; C134-A144; P160-R176; T189-R225; S248-K289; G356-
M414), mouse Sema3a (D75; W93-F117; A131-Y143; L157-P173; E185-P224; A251-S257; N271-
K288; A357-A401); human PLXNA1 (A46-H53; G66-Y72; A83- G301; G344-P352; L362-E422); human 
PLXNA2 (S43-H52; G65-Y71; A82-G299; G342-P350; I369-E420); human PLXNA3 (V28-H35; G49-F54; 
A65-G281; G324-P332; L342-E402) and human PLXNA4 (G45-H53; G66-Y72; T83-G299; G342-L350; 
L360-R420). The MOE protein-protein docking application was run without any further refinement. 
Energy was calculated with the GBVI/WSA ΔG empirical scoring function that depends on the 
average gain/loss of rotational and translational entropy, the selected force field, the coulombic 
electrostatics using a constant dielectric of ϵ=1, the solvation electrostatics, the van der Waals 
contribution to binding and the surface area, weighted by exposure. Obtained poses were analyzed 
by superposing to model and scored by energy. 
Mutant generation and analysis. The p.G166V mutation was introduced in all the generated 
complex models through the MOE Protein Design tool. The conformational space of the mutant vs 
the wild-type complexes was efficiently explored through low mode molecular dynamics (MD) 
simulations that allow sampling of an ensemble of rotational conformers both of mutated and of 
the surrounding amino acids, using the implicit solvation for minimizing and rearranging the lateral 
chains of wild-type and mutated SEMA3G. According to the default procedure, all atoms of the 
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mutated residue were left free to move; to avoid larger changes in the backbone conformation, 
backbone of residues within 4.5 Å were tethered. Residues farther than 4.5 Å were fixed and, to 
speed up the simulation, atoms farther than the non-bonded cutoff > 5 Å were marked as inert. 
After an ensemble is generated, conformations within an RMSD value < 0.25 Å (i.e., similar 
conformations) were removed. The remaining conformations were then scored and sorted using 
the stability scoring function. Conformations with relative energies of the global minimum higher 
than 10 kcal/mol were removed. Additionally, only the best 25 conformations were kept. All 
properties and scores are then averaged using the Boltzmann’s distribution. Amber10:EHT force 
field, with the Generalized Born implicit solvent model was used. 
Solvation studies. Solvation energy is calculated with the MOE potential energy tool. Esol is the 
implicit solvation energy calculated using the Generalized Born model (GB/VI). 
Solvent distribution analysis was performed using the MOE 3D-Reference Interaction Site Model 
(3D-RISM) tool.  
Cell lines. GN11 cells (gift from Prof. Radovick (34)) and COS-7 cells (ATCC) were grown in standard 
conditions (Dulbecco's MEM containing 1 mM sodium pyruvate, 100 mg/ml streptomycin, 100 U/ml 
penicillin and 10% FBS; Invitrogen). Cells were checked for mycoplasma contamination (MycoAlert 
Detection Kit, Lonza) monthly and were contamination-free. 
Expression vectors and conditioned media. The expression vectors for hPLXNA1 and A4 were kindly 
provided by Dr. Andrews. To introduce the c.497G>T (p.G166V) mutation into human SEMA3G gene, 
we mutated the expression vector using the QuickChange Lightning Site-Directed Mutagenesis Kit 
(Agilent Technologies) and the oligonucleotides FW 5’-ACCGCCCCCGGACACTTTCCACACTGC-3’ and 
RV 5’-GCAGTGTGGAAAGTGTCCGGGGGCGGT-3’. Expression vectors were transiently transfected 
into COS-7 cells using Lipofectamine 2000 (Invitrogen). Transfection efficiency was determined from 
3 independent transfections as a ratio of fluorescent positive cells to the total of DAPI positive cells 
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number. Conditioned media were collected 48 h after transfection and, if needed, concentrated by 
diafiltration with Microcon-30kDa Centrifugal Filter Unit (Millipore).  
Immunoblotting. Cells were lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 7.4) and 1% Triton X-100, 
supplemented with protease and phosphatase inhibitors (Roche). Lysates were centrifuged at 
13,000 rpm for 10min at 4°C and protein concentration determined with the Bradford assay (BIO-
RAD). Concentrated CM of transfected COS-7 cells were diluted 1:2 in Laemmli sample buffer (35). 
20 μg of protein lysate or 20 μL of concentrated conditioned media were used for SDS-PAGE; 
prestained Sharpmass VII (Euroclone) was used as protein molecular weight marker. Proteins were 
transferred to nitrocellulose membrane (BIO-RAD) and immunoblotted with the following 
antibodies: anti-cMyc (1:1000; Thermo Fisher Scientific (10)), rabbit anti-pAKT Ser473, rabbit anti-
AKT (1:1000 each; 9271 and 9272 Cell Signalling (10)) followed by secondary horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse antibodies (1:10000; Santa Cruz Biotechnology). 
Densitometric analysis of band intensity was performed using the Image J and the mean pixel 
intensity calculated. AKT/pAKT ratio was calculated and results represented as percentage in 
activation compared to the maximum value fixed as 100% of 3 independent experiments.  
Alkaline phosphatase (AP)-fusion protein-binding assay. COS-7, GN11 cells or WT E14.5 mouse 
sections were fixed for 5min in methanol, washed 5 times with PBS, incubated in PBS containing 
10% FBS for 30min, and then reacted with AP fusion proteins (SEMA3A, SEMA3G WT or mutant) for 
2h at room temperature, as previously described (9). For competitive assays, sections were first pre-
incubated with mutant SEMA3G-CM overnight and then reacted with SEMA3A-CM. Cells or sections 
were then washed for 5min each with PBS, fixed with 4% PFA for 2min at room temperature, and 
washed again. Endogenous AP was heat-inactivated by incubation at 65°C for 2h. Cell-bound, heat-
stable protein-AP activity was detected as an insoluble reaction product after incubation with 4-
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nitro blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Roche). 
Images were recorded using Zeiss Axioskop2 plus microscope equipped with a digital camera.  
Migration assays. Subconfluent GN11 cells were used for chemotaxis experiments using a 48-well 
Boyden’s chamber (Neuro Probe). For these experiments, GN11 cells were suspended in serum-free 
medium (105 cells/50 μL) and placed in the upper compartment of the Boyden chamber. 
Compartments were separated by a polycarbonate porous membrane (8 μm pores) pre-coated with 
gelatin (0.2 mg/mL). 28 μL of with the concentrated CM from COS-7 cells transfected with control 
expression vector or with expression vectors for SEMA3G, SEMA3GG166V or SEMA3A were placed 
into the lower compartment of the chamber. The chamber was kept in an incubator at 37°C for 2h. 
After 2h, cells that had migrated through the membrane separating the two compartments of the 
chamber were stained using the Diff-Quick kit (Biomap, Italy). Images were taken using a Zeiss 
Axioskop2 plus microscope with a 20× objective and analyzed with ISCapture software. Three 
random fields of stained cells were counted for each well, and the chemomigration expressed as 
relative fold-increase compared to the control-CM whose value was fixed to 1, from  t3 
independent experiments.  
Proliferation assays. GN11 cells were seeded in 24-well plates at a density of 5000 cells/well and 
grown for 24h in standard conditions (Dulbecco’s MEM containing 1 mM sodium pyruvate, 100 
mg/ml streptomycin, 100 U/ml penicillin and 10% FBS; Invitrogen). For proliferation assays, cells 
were cultured overnight without serum and then for 24h in the presence of control CM or CM 
expressing wild-type or mutated SEMA3G. We then determined the percentage of phospho-histone 
H3 (PHH3)-positive cells out of all DAPI-positive cells for each treatment group in 12 random pictures 
from 3 independent experiments.  
Image processing and quantifications. We used a Zeiss Axioskop2 plus microscope equipped with 
a TCH-5.0ICE digital camera to acquire bright-field images and a Leica TCS SPE1 confocal microscope 
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to acquire fluorescent images. All images were processed using Photoshop CS4 (Adobe Inc.). In some 
experiments, we combined bright-field images of ISH stainings with images of immunofluorescence 
staining after they were acquired on the same microscope; after imaging, the bright-field images 
were inverted and converted to RGB colour mode for superimposition with the confocal images. To 
determine the total number of GnRH neurons in E14.5 mouse heads or P80 mouse MPOA, 20 μm 
sagittal sections through each entire head/MPOA were immunolabelled for GnRH and all GnRH-
positive cells counted in each section, as previously described (9). For each genotype, we analysed 
at least three embryos, and all GnRH-positive cells were counted in each section of each head under 
a 40× objective. To quantify GnRH innervation of the ME, we calculated the percentage of stained 
area for each 20 μm-section over the whole ME of 3 mice for each genotype with ImageJ software.  
Bound AP-conjugated proteins to COS-7 cells overexpressing PLXNA1-4 was measured using the 
ImageJ software; control-CM has been used as baseline to calculate the fold change for each 
condition.  
Statistics. For all experiments, we calculated the mean of at least three independent samples. Data 
are expressed as mean ± standard error of the mean (s.e.m.). To determine statistical significance, 
we used the two-sided unpaired Student’s t test or, for multiple comparison, a One-way ANOVA 
followed by a Tukey post-hoc test or Two-way ANOVA followed by Bonferroni post-hoc test. A p-
value of < 0.05 (one asterisk) was considered significant; a p-value of < 0.01 was indicated with 2 
asterisks, a p-value of < 0.001 with 3 asterisks. Statistical analysis was performed using Prism4 
(GraphPad Software).  
RESULTS 
Two siblings from consanguineous parents show reproductive defects, dysmorphic features and 
developmental delay.   
We identified a patient with an unusual syndrome characterized by cryptorchidism, a poorly 
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developed scrotum, HH and facial dysmorphic features. The patient belonged to a consanguineous 
family of Pakistani origin, in which the parents were first cousins. He had a younger brother with 
similar features, and two elder sisters unaffected by the condition. The family pedigree is outlined 
in Fig. 1A. 
The proband (patient 1) was a 20-year-old male, who was born at 41 weeks of gestation after a 
normal delivery, with a birth weight of 2.8 kg. At birth, he presented with bilateral undescended 
testes, normal phallus, and a poorly developed scrotum. Bilateral orchidopexy was performed at 4 
years of age. He was subsequently noted to have very small bilateral atrophic underdeveloped 
testes and a small hypoplastic scrotum. Dysmorphic facial features noted in the patient include 
unusual prominent staring eyes, prominent nasal bridge, brachycephaly, synorphrys, a beaked nose. 
 small mouth and chin, a high palate and pointed ears with an over folded helix.  
A human chorionic gonadotropin (hCG) test performed at the age of 3.7 years showed a normal 
testosterone response with a peak at 14.5 nmol/L from a basal level of less than 0.7 nmol/L, 
confirming that the gonads are functioning well and are producing testosterone when stimulated. 
A GnRH test performed at the age of 3.7 years showed follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) levels of 4.1 IU/L for both hormones, as maximum response after 
stimulation. A 3-week hCG test performed at 11 years of age also showed a normal response with a 
maximum testosterone response of 19.5 nmol/L. Further, growth hormone (GH) stimulation test 
showed a maximum growth hormone response of 14.0 ng/mL. A diagnosis of HH, which is typically 
made at adolescence and characterized by low levels of testosterone in male individuals in the 
setting of low or normal levels of gonadotropins (LH and FSH) (4), was made at 15 years of age. 
Specifically, the proband presented with testicular volumes of 3 mL (right testis) and 2 mL (left testis) 
(testicular volume <4 mL at the age of 14 years indicates absent puberty; (4)), testosterone levels of 
0.9 nmol/L (normal levels at 14-15 years 3.5-18.7 nmol/L, (36)) and gonadotropin levels of 0.5 IU/L 
(FSH) and 0.6 (LH) (normal levels: FSH 1.9-12.4 and LH 2.0-8.6, (37)). At the same age a patient’s 
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height velocity of 4.0 cm per year was determined. During a follow-up visit after 7-months of 
testosterone and gonadotropin treatment, the patient’s testicular volumes increased to 5 mL and 4 
mL, respectively, and height velocity to 5.4 cm per year. 
Further testosterone injections (50 mg every four weeks) resulted in the linear growth and 
development of secondary sexual characteristics, leading to pubic and axillary hair growth and an 
increase in penile size in the patient.  The proband attained the expected mid-parental height.  
The younger brother was a 15-year-old male who was born at 36 weeks of gestation with an 
emergency lower segment caesarean section. The birth weight was not recorded. Antenatal scans 
showed a dilated large bowel, oligohydramnios and microcephaly. At birth, he presented with an 
anorectal malformation, and colostomy was performed at day 2 after birth. Subsequently, posterior 
sagittal anorectoplasty was performed at 1 year of age, followed by colostomy closure in the same 
year. The patient had bilateral undescended testes and a small phallus. Right orchidopexy was 
performed initially. Since the left testis was not palpable, left orchidopexy was performed later at 
the age of 9 years. The patient had also a hypoplastic scrotum. A hCG test performed at the age of 
2.7 years showed a normal testosterone response with a peak at 28.3 nmol/L from a basal level of 
less than 0.7 nmol/L. A GnRH test performed at the same age showed FSH and LH levels of 2.4 IU/L 
and 1.4 IU/L, respectively, as maximum response upon stimulation. A 3-week hCG test showed a 
maximum testosterone response of 22.2 nmol/L. 
The dysmorphic features of this patient included a small round head, beaked nose, and thin upper 
lips. The left helix was slightly unfolded, and the ear was slightly protruding. Growth hormone (GH) 
stimulation test (glucagon) in the patient with a maximum growth hormone response of 4.2 ng/mL, 
which combined with low IGF-1 serum levels (50 ug/dL; references range 150-400 ug/dL, (38)) 
suggested GH deficiency. Growth velocity 6 months after starting GH treatment, at 6 years old, was 
10 cm/year (normal 4-6 cm/year). Notably, sibling 2 attained height -1.0 SD below the mid-parental 
height. 
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Both patients were noted to have some developmental delay. Patient 1, at 5 years of age had a 
general development quotient of 60 in the severely delayed range. He had significant learning 
difficulties, was unable to speak in sentences and at 8 years of age was enrolled in a specialized 
school. Patient 2 began to walk at 2 years and 7 months and was not speaking by the age of 3 years. 
MRI of their brains as well as hearing and olfaction were normal in both brothers. The prolactin 
levels were normal and there were no features of hemochromatosis in both patients. The 
combination of the clinical features described above suggests that the two brothers may have a 
novel syndrome, as the constellation of these features has not been previously described. 
 
A point mutation in the SEMA3G gene was found in the two affected brothers. 
Due to the unique presenting features of the two patients including the birth from consanguineous 
parents, an autosomal recessive disease with a homozygous genetic pattern of inheritance was 
suspected. HZM was performed on the two patients and their two unaffected sisters to identify 
candidate genes, followed by exome sequencing. The shared homozygous regions found in the 
affected patients, and absent in the unaffected siblings, are presented in Table 1. In total, the 
affected brothers shared approximately 85 Mb of unique homozygous region which contained over 
600 protein-coding genes. The largest shared region, around 38 Mb, was found on chromosome 3 
(Table 1 and Fig. 1B).  
Variants from exome sequencing data found in the homozygous regions were filtered to narrow 
down the list of variants. First, the variants that disrupted gene function, by causing a non-
synonymous or a stop gain change in the protein coding sequence, or affected the splice site, were 
identified. The remaining variants were filtered out. The homozygosity mapping data were next 
used in conjunction with the filtered variants to identify those lying within all the shared 
homozygous regions. As we hypothesized an autosomal recessive disorder, we next filtered for 
homozygous mutations in these regions. Finally, the variants found in a homozygous state in SNPs 
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databases (dbSNP130 and 1000 Genomes project) were filtered out, leaving those unique to the 
patients, within the shared homozygous regions. Specifically, this analysis identified SEMA3G as a 
potential candidate gene, with nucleotide change c.497G>T and protein change p.Gly166Val 
(p.G166V). This variant had previously been reported in databases such as gnomAD, ExAC and 
dbSNP (rs549122188) with global minor allele frequencies (MAF) < 0.05%; yet, no homozygous 
variants have been reported so far.  
As class 3 semaphorins and their receptors have been extensively implicated in the pathogenesis of 
HH and in the GnRH neuron physiology (14,15), we considered SEMA3G as the main candidate to 
explain the HH phenotype in our patient. In addition, no mutations in known HH genes were found. 
Sanger sequencing confirmed the novel change to be present in the homozygous state in the two 
affected patients. Both parents and the eldest sister were heterozygous carriers for the mutation, 
and the second sister was homozygous for the normal reference allele (Fig. 1C). The c.497G>T 
(p.G166V) mutation substitutes an ambivalent glycine residue with a hydrophobic valine residue 
and is predicted to be possibly damaging and disease causing according to PolyPhen (39), SIFT (40) 
and MutationTaster (41) bioinformatic tools, respectively (Fig. 1D). The p.G166V mutation resides 
in the SEMA domain which is characterized by a conserved set of cysteine residues, forming four 
disulphide bonds that stabilize the structure (Fig. 1E). The mutated residue affects a glycine residue 
that is conserved between vertebrates (Fig. 1F).  
 
Sema3g expression during mouse GnRH neuron and pituitary development.  
Because other class 3 semaphorins and their receptors/co-receptors NRPs/PLXNs are 
implicated in mouse GnRH neuron development and in the pathogenesis of HH (11,15), we applied 
mouse as model organism to study the expression pattern of Sema3g and its functional requirement 
in the GnRH neuron system. In wild-type mice, GnRH neurons are first detected at embryonic day 
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(E) 10.5 in the nasal pit, migrate in the nasal compartment and then in the basal forebrain, where 
they reach the hypothalamus. The migration starts at approximately E11.5 and it is completed just 
before birth (42). Thus, to get insights into the expression pattern of Sema3g during GnRH neuron 
development, we performed in situ hybridization (ISH) for Gnrh and Sema3g on adjacent sections, 
at E12.5, E13.5 and E14.5. As shown in Suppl. Fig. 2, Sema3g was expressed between E12.5 and 
E14.5 along the nasal septum in areas including the migratory path of GnRH neurons (43). This 
expression pattern suggested a possible role of Sema3g in the navigation of GnRH neurons in the 
nasal compartment. To check whether the Sema3g+ cells were GnRH neurons, we performed double 
in situ-immunofluorescence protocols using the Sema3g probe and an anti-GnRH antibody. We 
found that these two cell populations were distinct with no co-expression of Sema3g in GnRH 
neurons (Fig. 2A). Thus, to further characterize the cell type expressing Sema3g along the GnRH 
neuron migration in the nose, we performed similar experiments with markers for neurons (Tuj1) 
(Fig. 2B), olfactory ensheathing cells (OECs; S100) (Fig. 2C) or blood vessels (isolectin-B4, IB4) (Fig. 
2D). In agreement with previous reports (19,20) we found that Sema3g-expressing cells were 
endothelial cells, as evidenced by the co-localization of Sema3g mRNA and the IB4 staining (Fig. 2D). 
We also found expression of Sema3g mRNA transcripts in the developing hypothalamus and 
pituitary (Fig. 2E-I). Notably, expression of Sema3g was detected in the anterior lobe of the 
developing pituitary gland with a peak of expression at E12.5 (Fig. 2F). Sema3g was also expressed 
in the ventral and anterior hypothalamic region at this stage, and expression declined at E18.5 (Fig. 
2I). 
These observations were consistent with a possible requirement for Sema3g during GnRH 
neuron migration from the nasal compartment to the hypothalamus as well as in the developing 
pituitary. We therefore examined GnRH neuron migration and pituitary development in Sema3g-
null mice. 
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Sema3g loss affects the development of GnRH neurons and pituitary 
As patients carry homozygous mutation of SEMA3G (Fig. 1) and we detected expression of 
Sema3g in the nasal compartment (Fig. 2), we first asked if Sema3g-null mice (17) showed impaired 
GnRH neuron development. Immunohistochemical GnRH staining of coronal sections followed by 
counting the GnRH-positive cells in each head demonstrated a reduced number of GnRH neurons in 
mutants compared to wild-type mice at E14.5 (Fig. 3; GnRH neuron number ± s.e.m.; Sema3g+/+ 
1172.0±80.3 vs. Sema3g-/- 811.3±44.8; * p=0.017; two-sided unpaired Student’s t test, n=3 for each 
group). Because GnRH neurons at E14.5 can be observed in the nose, in the nasal-forebrain junction 
(NFJ) and in the forebrain (FB), we next determined the relative number of neurons in these three 
compartments. We observed a similar number of GnRH-positive cells in the nose and in the NFJ of 
mutants compared to wild-types, with a significantly reduced number in the FB of mutants 
compared to wild-type mice (Fig. 3A-B; nose: Sema3g+/+ 366.0±68.0 vs. Semag3–/– 342.0±42.7, 
p>0.05; nfj: Sema3g+/+ 295.3±27.2 vs Semag3–/– 244.7±15.6, p>0.05; fb: Sema3g+/+ 511.0±31.3 vs. 
Sema3g–/– 224.7±34.1, ** p=0.004; two-sided unpaired Student’s t test, n=3 for each group). We 
therefore examined whether Sema3g was required for the survival of GnRH neurons in the 
developing brain. For this analysis, we labelled adjacent coronal sections through the MPOA, where 
most GnRH neurons reside at E14.5, with antibodies against GnRH or activated caspase-3, a marker 
for cells committed to undergo apoptosis. As shown in Suppl. Fig. 3A, we did not detect apoptotic 
cells in the forebrain of either wild-type or Sema3g-/- mice, thus excluding that the reduced number 
of GnRH neurons in the forebrain may be due to GnRH neuron cell death via apoptosis. Activation 
of caspase-3 was detected at normal levels in the salivary gland, used as positive control (44), of 
both genotypes (Suppl. Fig. 3A). 
To assess whether the GnRH neuron migration defect observed in knockout mice could be 
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due to alterations in the patterning of blood vessels (BV) and olfactory/vomeronasal (OLF/VN) axons 
present in the nasal compartment (9,24), we stained the BV and OLF/VN nerves of wild type and 
Sema3g-/- mice for IB4 and peripherin, respectively. We observed the presence of BV without overt 
vascular defects (Suppl. Fig. 3B) and normal patterning of OLF/VN axons (Suppl. Fig. 3C), in Sema3g-
null mice compared to wild-types. Similarly, immunostainings for Endomucin and Pecam did not 
reveal differences in the patterning of BV in the developing pituitary of mutant compared to wild-
type littermates at E14.5 (Suppl. Fig. 4). 
Taken together, these data are consistent with a primary direct role for Sema3g signaling in 
GnRH neurons, rather than indirect effects of Sema3g-dependent OLF/VN nerves or BV on GnRH 
neuron development.  
In addition, because Sema3g was also expressed in the developing pituitary (Fig. 2B), we analyzed 
the expression of pituitary cell lineage commitment markers in Sema3g–/– embryos to assess if 
Sema3g might also control pituitary development. Specifically, by using ISH, we analyzed the 
expression of Pit1, which is required for somatotrophs, thyrotrophs and lactotrophs (45–47), 
Pomc1, which gives rise to corticotrophs and melanotrophs (48,49) and the α-glycoprotein subunit 
(α-GSU), which is expressed by gonadotrophs and Pit1-independent thyrotophs (50). No differences 
were observed in the expression of Pomc1 (Fig. 3C), whereas we observed a modest reduction of α-
GSU and Pit1 at E14.5 in the Sema3g–/– pituitaries compared to wild-type littermates. These 
observations are consistent with a developmental delay in the differentiation of some pituitary cell 
lineages, however terminal differentiation of hormone producing cells was not affected. 
Hypothalamic GnRH neuron number, pituitary gonadotrope cells and testes morphology are 
normal in the adult Sema3g-null mice 
To evaluate whether the developmental defects of GnRH neurons observed in Sema3g-null 
mice during fetal life impact adult fertility, we analyzed the HPG axis of Sema3g-null mice. In adults, 
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GnRH neurons are mainly located in the MPOA of the hypothalamus and project to the median 
eminence (ME), where they release GnRH into the portal BV of the pituitary. We therefore analyzed 
the GnRH neuron complement in the hypothalamus of adult (P80) Sema3g-null mice and observed 
a small but not significant reduction in the number of GnRH neurons reaching the MPOA in mutants 
compared to wild-types (Fig. 4A,B; GnRH neurons ± s.e.m.; MPOA: Sema3g+/+ 353.8±39.7 vs. 
Semag3–/– 298.0±31.8, p>0.05, p=0.315; two-sided unpaired Student’s t test, n=4 for each group). 
Yet, the innervation of the ME appeared normal in both genotypes, as confirmed by measuring pixel 
intensity of the GnRH immunoreactive neurites (Fig. 4A,B; % of stained area: Sema3g+/+ 1.9±0.2 vs. 
Semag3–/– 2.1±0.3; p>0.05, p=0.195; two-sided unpaired Student’s t test, n=4 for each group).  
Consistent with a normal innervation of the ME, we did not observe any differences in the 
expression of terminally differentiated hormone-producing cells in the adult (P80) pituitary gland of 
the Sema3g-/- mutant animals compared to wild-type control littermates (Fig. 4C). Similarly, the size 
and morphology of wild-type and mutant testes were overall normal (Fig. 4D). Although histological 
examination of sections stained with H&E revealed a small but significant reduction in the density 
of seminiferous tubules (mean count/mm2 ± s.e.m.; Sema3g+/+ 16.3±0.8; Semag3–/– 14.2±0.5; * 
p=0.032; Student’s t -test, n=3 for each group), Sertoli cells (stained with an anti-Sox9 antibody) and 
Leydig cells (stained with an anti-Cyp17a1 antibody) appeared normal in both genotypes. 
Consistently, qPCR experiments (Fig. 4E) showed normal levels of Sox9 and Cyp17a1 in both 
genotypes (Cyp17a1 relative expression: Sema3g+/+ 0.9±0.1 vs Sema3g-/- 0.8±0.23, p=0.580; Sox9 
relative expression: Sema3g+/+ 1.0±0.03 vs Sema3g-/-  0.9 ± 0.2, p=0.482; n=3 for each group, two-
sided unpaired Student’s t test). 
Overall, although we found that Sema3g was expressed during fetal life and its loss affected GnRH 
neuron development, a normal HPG axis was reached in adult Sema3g null mice.  
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The p.G166V mutation affects the affinity of SEMA3G to its PLXNA receptors in silico. 
Because the analysis of homozygous null mice did not fully phenocopy the GnRH deficiency present 
in the brothers carrying SEMA3GG166V mutation, we first studied the possible effect of the mutation 
in silico, by computational modelling. According to the available modelling data, class 3 semaphorins 
bind as a dimer to a receptor complex formed by two plexins and two neuropilins (33). Thus, to 
predict the possible impact of the SEMA3G mutation on binding properties and stability of this 
ternary complex, we first performed in silico modelling studies.  
To date, mouse Semaphorin 3A (mSema3a) is the only class 3 semaphorin co-crystallized in a ternary 
complex with mouse Neuropilin-1 (mNrp1) and Plexin A2 (mPlxna2) and shares 46% identity with 
hSEMA3G, making it a suitable template for homology modelling (51,52). Thus, to investigate the 
affinity of wild-type SEMA3G for the different PLXNAs, four comparative models of the 
SEMA3G::PLXNA1-4 complexes were built and their relative orientation was checked through 
protein::protein docking. Binding free energy results indicated that SEMA3G binds in order of 
affinity to PLXNA4 (ΔG = -19.2 kcal/mol), PLXNA3 (ΔG = -17.6 kcal/mol), PLXNA1 (ΔG = -15.6 
kcal/mol) and PLXNA2 (ΔG = -10.9 kcal/mol). 
Modelling data also predicted that the SEMA3GG166V mutation located at the interaction interface 
between SEMA3G and PLXNAs. Thus, the impact of the mutated residue on protein stability was 
evaluated through Low Mode Molecular Dynamics (MD), which allows to predict changes in protein 
stability upon mutation based on a scoring function trained on over 3000 single point reported 
mutations (53,54). Interestingly, we found that the mutation overall stabilizes the formation of all 
the four complexes and induces an increase in affinity for all four PLXNAs (Table 2), with the greatest 
value for PLXNA1 (Δ Affinity = -8.2 kcal/mol). To further characterize the impact of mutation on the 
binding to PLXNA1, which is implicated in HH, subsequent analyses were therefore focused on the 
SEMA3G::PLXNA1 complex (Suppl. Fig. 5).  
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To better describe the contribution of each residue at the interaction interface between SEMA3G 
and PLXNA1, a protein contact analysis was carried out on Boltzmann’s average structures 
generated by the conformational sampling of the residues around the mutation and provided by 
the Low Mode MD approach. Compared to SEMA3GG166V, wild-type SEMA3G showed a different 
network of interactions with PLXNA1 (Suppl. Table 1), likely due to a backbone rearrangement upon 
mutation rather than to a direct interaction of Gly or Val 166 with PLXNA1. For example, in wild-
type SEMA3G, Arg167 can form two ionic interactions and a hydrogen bond with PLXNA1 Asp410, 
whereas Arg167 of mutated SEMA3G can only form one ionic interaction with PLXNA1 Asp410 (Fig. 
5A, upper panels). Besides Arg167, other residues contribute to the interaction between SEMA3G 
and PLXNA1; however most of these residues are distributed along the whole interaction interface 
and far from the mutated residue (Suppl. Table 1). Overall, the analysis of contributions of each 
single interaction to the affinity of SEMA3G for PLXNA1 resulted in an energetic gain of -1.9 kcal/mol 
for SEMA3G mutant vs. the wild-type form. Although the Low Mode MD method predicted an 
affinity gain value that is approximately 4-fold higher compared to this value (-8.2 kcal/mol vs -1.9 
kcal/mol), the different results could be due to the effect of solvation in the affinity calculations 
through the use of the Generalized Born (GB) implicit solvent model (55). In line with this hypothesis, 
the solvation analysis showed that the overall solvation energy is more favorable in the wild-type 
complex, with a difference of approx. -87.0 kcal/mol. Conversely, the mutant complex showed a 
gain in solvation energy of -39.6 kcal/mol, of which only -9.9 kcal/mol are ascribable to V166. These 
results suggest that the p.G166V mutation increases SEMA3G affinity by reducing solvation energy 
of the interacting amino acids without influencing the amino acid interaction network. Consistent 
with this result, the solvation of unbounded SEMA3G wild-type seems to be favored (wild-type = -
1789.8 kcal/mol vs SEMA3GG166V = -1569.0 kcal/mol). 
Further, by applying a 3D-Reference Interaction Site Model (RISM), which provides the solvent 
structure in the form of a 3D site distribution function, the presence of a cluster of water molecules 
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(blue mesh surface) around the position of the mutation was found in both WT and mutated 
SEMA3G. The two complexes also presented a different extension of positive free energy at the 
surface (solid red), suggesting that the increased affinity of SEMA3GG166V for PLXNA1 could also 
depend on water reorganization around the mutated residue. The analysis of the water-accessible 
surfaces showed then a positively-charged patch around the mutation area, that was significantly 
higher for SEMA3GG166V compared to wild-type (Table 3, mutant 284.3 Å2, wild-type 167.6 Å2, shown 
in blue in Fig. 5A, lower panels). 
In summary, our in silico analyses showed that the mutation was likely to induce a change in 
receptor binding selectivity with a significant increase in the binding affinity of mutated SEMA3G for 
its canonical ligand PLXNA4 and ectopically to PLXNA1. This could be due to the ability of the 
p.G166V mutation to induce a local rearrangement of the surrounding amino acids and water 
molecules, and to the stabilizing effect of the positive patches. 
 
SEMA3GG166V binds to PLXNA1-expressing COS-7 cells with higher affinity compared to wild type. 
To corroborate the in silico findings and to test whether the mutation found in the patients 
determined an increased affinity for PLXNA1 also in vitro, we set up binding assays on PLXNA4 or 
PLXNA1-overexpressing cells using alkaline-phosphatase (AP)-conjugated c-Myc-tagged human 
SEMA3G (17) and SEMA3GG166V ligands. 
 We first performed immunostainings and immunoblotting assays using an anti-c-Myc antibody 
to establish that both proteins were expressed and effectively secreted in COS-7 cells (Fig. 5B,C). 
We then used the conditioned medium (CM) of COS-7 cells expressing wild-type (17) or mutated 
SEMA3G for binding assays on COS-7 transiently expressing human PLXNA4 or PLXNA1. Both wild-
type SEMA3G and SEMA3GG166V bound to PLXNA4 or PLXNA1-expressing COS-7 cells (fold change of 
integrated density vs control-CM: wild-type SEMA3G 89.3±36.8, SEMA3GG166V 296.5±71.1 for 
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PLXNA4; wild-type SEMA3G 20.9±5.1, SEMA3GG166V 117.6±20.2 for PLXNA1; Fig. 5D). Moreover, and 
in agreement with the in silico predictions, the mutated one bound 3-fold and 6-fold more to 
PLXNA4 and PLXNA1, respectively, compared to the wild-type (Fig. 5D), as shown by a more intense 
staining of the reacted cells (fold change of SEMA3GG166V vs wild-type SEMA3G: 3.3±0.8 PLXNA4, 
*p=0.038; PLXNA1 5.6±1.0, **p=0.004; n=4 for wild-type SEMA3G; n=3 for SEMA3GG166V; two-sided 
unpaired Student’s t test).  
Taken together, these results confirmed that the p.G166V mutation altered receptor binding 
properties and affinities by making the SEMA3G protein highly affine for its canonical receptor 
PLXNA4 but also for PLXNA1. These results are also suggestive of a potential action in vivo of 
mutated SEMA3G, which could interfere with other PLXNA1-mediated signaling molecules such as 
SEMA3A, known to be essential for GnRH neuron migration (9,11,16).  
 
SEMA3GG166V interferes with SEMA3A binding to embryonic nasal and forebrain tissues  
To test this hypothesis, we performed competitive binding assays also in vivo with SEMA3A-AP 
on normal tissues or tissues pre-incubated with mutant SEMA3G. We confirmed that SEMA3A binds 
on the nasal tissue of E14.5 mouse sections (9) as well as on the striatum and on the cortex of E14.5 
sections (Fig. 5E, left panels) (56). Instead, when the sections were pre-absorbed with SEMA3GG166V, 
the enzymatic reaction of the AP-bound SEMA3A was less efficient (Fig. 5E, right panels). Although 
qualitative, these results suggest that mutated SEMA3G may interfere with other SEMA3-signals 
that are essential for GnRH neuron development to indirectly cause GnRH deficiency. 
 
Mutated SEMA3G protein affects GN11 cell behavior and response to SEMA3A. 
Because we observed that Sema3g was physiologically expressed in the nasal compartment where 
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it affected GnRH neuron development, we used GN11 as an established model of immature 
migrating GnRH neurons (34) to study the cellular and biochemical mechanisms through which wild-
type and mutated SEMA3G may affect GnRH neurons.  
Because GN11 express Nrp1 and Nrp2 (57) as well as Plxna1, Plxna2, Plxna3 and Plxna4 (Fig. 
6A) receptors, these cells represent a suitable model to study the effects of wild-type vs mutated 
SEMA3G. We first tested binding abilities of wild-type and mutated SEMA3G-CM and we did not 
find differences (Fig. 6B), possibly because GN11 cells express all the SEMA3G receptors and co-
receptors making difficult to detect altered binding properties to the different single receptors. We 
then used GN11 cells to study the effects of SEMA3G on the migratory activity of GnRH neurons 
because GN11 show a strong chemomigratory response in vitro (24,55). For these experiments, 
GN11 neurons were exposed to control CM or to CM of COS-7 cells transfected with wild-type or 
mutated SEMA3G for 2h. We found that the chemomigration of GN11 cells was significantly 
increased in the presence of wild-type SEMA3G compared to control (CTRL) media. Instead the 
difference between CTRL and mutant SEMA3G did not achieve statistical significance (expressed as 
relative migration vs control-CM: wild-type SEMA3G 1.5±0.1; SEMA3GG166V 1.2±0.1; CTRL vs WT ** 
p=0.003; CTRL vs G166V p=0.251; WT vs G166V P=0.085 ; One-way ANOVA followed by Tuckey post-
hoc test, n=7) (Fig. 6C).  
Further, to investigate whether the mutated protein might interfere with SEMA3A also in 
this cellular model, GN11 cells were exposed to SEMA3A alone or in the presence of WT or mutant 
SEMA3G. As expected, SEMA3A inhibits the chemomigration of GN11 cells (9); a similar effect is still 
observed in the co-presence of SEMA3A and WT SEMA3G suggesting that the WT SEMA3G does not 
compete with SEMA3A. Instead, when GN11 cells were co-exposed to SEMA3A and mutant SEMA3G 
the inhibitory effect of SEMA3A was almost abolished, with a number of migrated cells that was 
similar to the control media (expressed as relative migration vs control-CM: SEMA3A 0.5±0.04; 
SEMA3A+WT SEMA3G 0.5±0.1; SEMA3A+SEMA3GG166V 0.9±0.2; CTRL vs 3A * p=0.011; CTRL vs 
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3A+3G WT * p=0.011; CTRL vs 3A+3G G166V p=0.808 ; 3A vs 3A+3G G166V * p=0.035; 3A+3G WT vs 
3A+3G G166V * p=0.038; One-way ANOVA followed by Tukey post-hoc test, n=3).  
Altogether these results suggested that mutant SEMA3G was less effective in promoting 
GN11 cell migration and prevented the effects of SEMA3A, likely by its binding to PLXNA1 receptor. 
To study the effects of p.G166V mutation on the activation of signaling pathways previously 
implicated as downstream effectors of semaphorins in GnRH neuron cell lines, we analyzed the 
activation of AKT (10,12,58) in GN11 treated with wild-type or mutated SEMA3G. GN11 cells were 
serum-starved overnight and then treated with concentrated CM (wild-type SEMA3G and 
SEMA3GG166V) for 5-60min. We observed that wild-type SEMA3G could induce the activation of AKT 
with a peak after 60min, whereas SEMA3GG166V was less effective (mean of the relative percentages 
of activation ± s.e.m: WT 5’: 49.3±2.9; WT 15’: 55.3±3.6; WT 30’: 78.3±6.4; WT 60’: 100; MUT 5’: 
18.4±1.7; MUT 15’: 21.0±7.8; MUT 30’: 36.9±14.4; MUT 60’: 53.3±9.6; WT vs MUT: * p=0.025 (5’), * 
p=0.011 (15’), ** p=0.002 (30’), *** p=0.0006 (60’); Two-way ANOVA followed by Bonferroni post-
hoc test, n=4) (Fig. 6D).  
Because AKT signaling is also involved in cell proliferation, we tested the effects of wild-type 
and mutated SEMA3G on GN11 cell proliferation. For this experiment, GN11 cells were serum-
starved overnight and then treated with control, wild-type or mutated SEMA3G concentrated CM, 
for 24h. We found that SEMA3G induced an increase of approximately 50% in the proliferation of 
GN11 cells, measured by counting the number of PHH3+ cells, compared to control. Instead, 
SEMA3GG166V was less effective in promoting GN11 cell proliferation (Fig. 6E; PHH3+ cells/field ± 
s.e.m.; control CM 9.2±0.5; wild-type SEMA3G 18.3±1.5; SEMA3GG166V 7.0±0.5; ** p=0.001 (control 
CM vs wild-type SEMA3G), p=0.294 (control CM vs SEMA3GG166V), *** p=0.0003 (wild-type SEMA3G 
vs SEMA3GG166V); One-way ANOVA followed by Tuckey post-hoc test, n=3). Taken together, these 
observations suggested that SEMA3G activated AKT signaling and promoted migration and 
proliferation of immature GnRH neurons, whilst the SEMA3GG166V mutation interfered with these 
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functions.  
Based on findings in the genetic Sema3g-null mouse model, combined with the identification 
of a SEMA3G mutation in two brothers with HH and our tissue culture studies using recombinant 
wild-type and mutated SEMA3G, we demonstrated that SEMA3G may act physiologically to control 
GnRH neuron development, but its role is redundant in adulthood. Yet, mutated SEMA3G may 
interfere with other PLXNA-dependent signaling pathways to indirectly cause GnRH deficiency, 
including HH. 
 
DISCUSSION 
Here, we identified two brothers born from consanguineous parents who were affected by a novel 
syndrome characterized by reproductive defects, facial dysmorphic features and developmental 
delay.  
Both brothers showed cryptorchidism during infancy and absence of response to GnRH stimulation 
test in early childhood, which can be both suggestive of HH (4). Further, although the hCG test 
performed in early childhood was normal, there are evidences showing that 50% of boys with HH 
and cryptorchidism showed a normal testosterone response to hCG stimulation and that hCG can 
be used in pediatric practice as a treatment for boys with HH (59–64). An HH diagnosis was therefore 
suspected and confirmed for the older brother who presented at 15 years with typical settings of 
hypogonadal testes and hormonal levels (testosterone and gonadotropins). 
Based on the pattern of inheritance of this disorder, the composition of the family trio with 
unaffected and affected siblings and the consanguineous marriage, we hypothesized an autosomal 
recessive syndrome. Thus, by combining HZM with exome sequencing and filtering strategies we 
identified a mutation in the SEMA3G gene within the shared homozygous region on chromosome 
3. Because HH is the major feature of our probands and class 3 semaphorins play essential roles in 
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GnRH neuron development and, when mutated, can cause HH/KS (9,10,12,13), we performed 
expression and functional experiments to study the possible role of Sema3g in the GnRH system. 
We found that Sema3g mRNA is expressed in the nasal compartment with a spatial and temporal 
pattern similar to other class 3 semaphorins and their receptors (e.g Sema3a, Nrp1-2) (9,11). In 
agreement with previous reports showing Sema3g expression on BV (17,19), Sema3g+ cells 
navigating in the nasal parenchyma are endothelial cells, which have been previously proposed to 
form a neurovascular niche along migrating GnRH neurons (24,65). Interestingly, a recent paper has 
shown that endothelial Sema3g regulates synaptic plasticity in the brain (19), strongly supporting a 
role for this molecule as interplay between vascular and nervous systems.  
Our expression studies also highlighted Sema3g expression in the developing pituitary gland 
and hypothalamus, which represent additional key players in the HPG axis that control 
reproduction.  
Because the patients carried homozygous mutations of SEMA3G, at first instance we 
analyzed homozygous Sema3g-null mice to model human mutation and functionally study the 
requirement of Sema3g in the development of the GnRH system. We found a decreased number of 
GnRH neurons reaching the FB of Sema3g-null mice compared to wild-types during embryonic 
development. Yet, Sema3g-/- adult brains contained a normal number of neurons in the MPOA and 
exhibited an equally innervated ME. In line with these results, no gross alterations were found in 
testes morphology or in the terminal differentiation of pituitary cells. Although a moderate decrease 
in α-GSU+ gonadotrophs and Pit-1-independent thyrotrophs during development, these changes are 
likely due to a developmental delay in lineage differentiation. 
Phenotypic differences between embryonic and adult stages might be explained by 
redundant signaling of semaphorins and their receptors/co-receptors (66), whose lack in vivo could 
be compensated by other members of the family controlling GnRH neuron migration. In agreement, 
Sema4d- and Gnrh1Cre;Itgb1fl/fl-null mice show a defective GnRH neuron development, but present 
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a normal HPG axis in adulthood (67,68).  
Further, given the nature of the mutation, which is predicted to cause receptor binding alterations, 
homozygous Sema3g-null mice may not represent the optimal model to functionally validate the 
mutation pathogenicity. With advances in genome editing, it would be interesting to confirm our in 
silico and in vitro results by generating a knock-in mouse carrying the SEMA3G mutation at the 
homologous human position (69).  
The increased stability of SEMA3GG166V-PLXNA1 complex is also in line with our in vitro experiments 
on COS-7 cells, in which the mutation induces increased binding to PLXNA1 receptor compared to 
wild-type SEMA3G, and on immortalized GnRH neurons, which express both PLXNA4 and PLXNA1 
receptors. The latter experiments revealed that mutated SEMA3G is less effective in promoting 
migration, proliferation and AKT activation, compared to wild-type. This could be due to PLXNA1 
binding by mutant SEMA3G with a higher affinity than the wild-type counterpart, leading to reduced 
ligand availability to bind its canonical co-receptor PLXNA4 and to promote GN11 migration. 
Alternatively, the increased affinity of mutant SEMA3G for PLXNA1 might induce a downstream 
signaling cascade that acts by suppressing PLXNA4-promoted neuronal migration, proliferation and 
AKT activation. Interestingly, PLXNA1, which in mouse mediates Sema3a-dependent VN patterning 
in the nose, can be mutated in patients with HH (11). Thus, in vivo, mutated SEMA3G might interfere 
with the SEMA3A/PLXNA1 signaling in the nose, and indirectly cause HH. Accordingly, our 
competitive binding assays with mutant SEMA3G and wild-type SEMA3A on tissues and GN11 cells 
support this hypothesis, as revealed by the less effective binding of SEMA3A on tissues pre-absorbed 
with mutant 3G and by the reduced response of GN11 cells to SEMA3A when co-exposed to mutant 
SEMA3G. 
In conclusion, we have identified two brothers born from consanguineous parents and 
affected by a novel syndrome characterized by HH, facial dysmorphic features and intellectual 
disabilities. By combining homozygosity mapping with exome sequencing, in silico, in vitro and in 
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vivo mouse models, we provided evidence that SEMA3G affects GnRH neuron development and 
altered SEMA3G signaling might indirectly cause HH.   
Finally, given the complexity of this disease and the nature of the mutation, further genetic 
and functional studies will be necessary to understand if the phenotypic spectrum of the patients 
might arise from additional mutated genes and if similar mutations may be found in unrelated 
patients.  
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FIGURES LEGENDS 
 
Figure 1. Homozygosity mapping identifies a SEMA3G mutation in two brothers affected by reproductive 
defects, dysmorphic features and developmental delay.   
 (A) Pedigree of the affected brothers. Circle denotes female; square denotes male; black square denotes 
affected male. (B) The panel shows a B-allele frequency plot of chromosome 3, with heterozygous SNPs 
plotted at 0.5, and homozygous SNPs plotted at either position 0 or 1. Highlighted in green are the 
homozygous regions. As seen from the image, a large region spanning base pair positions 27663546 to 
65514406 (approximately 38 Mb) is shared between the two affected patients. This homozygous region is 
absent in the unaffected siblings. A small homozygous region of 1.3 Mb is also presented in the figure. This 
represents the largest shared homozygous region on chromosome 3. (C) Chromatograms of nucleotides 492 
to 501 of the SEMA3G coding sequence from 2 brothers carrying a nucleotide substitution in exon 5 (left side, 
forward strand; right side, reverse strand; the positions of the G>T and corresponding C>A change are 
indicated with asterisks) and from the unaffected parents and sisters. (D) In silico analysis identified SEMA3G 
on chromosome 3 as a potential candidate gene, with nucleotide change c.497G>T and protein change 
p.Gly166Val. PolyPhen-2, SIFT and Mutation Taster were used to predict structural and functional effects of 
p.G166V amino acid substitution on SEMA3G protein structure and function. The mutation was predicted to 
be possibly damaging (Poly-Phen), damaging (SIFT) and disease causing (Mutation Taster) with probabilistic 
scores above 0.99. (E) Diagram of the SEMA3G functional domains: SEMA and Ig-like. Their position and the 
position of the mutated amino acid residue within the protein sequence are indicated. (F) Genomic 
evolutionary rate profiling of sequence constraint for the SEMA3G mutation in the 2 brothers using GERP++ 
analysis provided an RS score of 3.79, which is close to the maximum score of 6.18 for complete conservation 
across all mammalian species. (G) Alignment of partial protein sequences of vertebrate SEMA3G orthologues 
shows that the G166 residue is evolutionarily conserved in humans and several other vertebrate species. 
 
Figure 2. Sema3g mRNA expression during GnRH neuron and pituitary development. 
(A-D) Sema3g ISH (green signal) of coronal sections from E13.5 heads at the level of the nasal region followed 
by immunolabelling (red) for GnRH (A) or Tuj1 (B) or S100 (C) or IB4 (D) revealed that Sema3g is expressed 
by cells in close apposition to GnRH neurons, Tuj1+-olfactory neurons and to S100+ OECs (white arrows). 
White arrowheads indicate examples of Sema3g+ cells co-expressing endothelial marker IB4. (E-I) Sema3g 
ISH on sagittal (E-H) and frontal (I) histological sections of wild-type pituitaries using antisense riboprobes 
against Sema3g. (E’-I’) are magnified images of the squared areas in A-E, respectively. (E-E’) At E10.5, weak 
staining for Sema3g is observed in some cells of the Rathke’s pouch, which is the primordium of the pituitary 
gland, and the ventral diencephalon. (F-F’) At E12.5, a peak in Sema3g mRNA expression is observed in the 
rostral and the ventral part of the developing anterior lobe of the pituitary gland (arrowhead). Positive 
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staining is also detected in the developing hypothalamus (arrows). (G-G’) At E14.5, expression is observed in 
the hypothalamus (arrows) and in some cells scattered throughout the developing anterior pituitary. (H-H’) 
At E15.5, Sema3g expression is found only in a few cells of the anterior lobe of the pituitary gland and it 
becomes almost undetectable at E18.5 (I-I’). Abbreviations: VD, ventral diencephalon; RP, Rathke’s pouch; 
HYP, hypothalamus; AL, anterior lobe; INF, infundibulum; PL, posterior lobe; IL, intermediate lobe. Scale bars: 
200 μm (A-D, low magnifications), 50 μm (A-D, high magnifications).: 200 µm (E-H), 100 µm (E’-I’). 
Abbreviations: OE, olfactory epithelium; VNO, vomeronasal organ; NFJ, nasal forebrain junction.  
 
Figure 3. Sema3g-null embryos display developmental defects in GnRH neuron migration and pituitary cell 
lineage.  
(A) Coronal sections of wild-type and Sema3g-null embryo heads at E14.5 were immunolabelled for GnRH to 
reveal GnRH neurons in the nasal compartment (panels in first column), in the NFJ (panels in second column) 
and in the MPOA (panels in third column). Black dots indicate border with OB. Black arrowheads indicate 
examples of migrating GnRH neurons in the nose, black arrows indicate examples of neurons crossing the 
OBs. Migrating GnRH neurons in the FB are indicated with black arrowhead while lack of GnRH neurons in 
the FB of mutants is indicated with '  (B) Quantitative counting analysis (expressed as mean ± s.e.m) 
showing a significant reduction in the total number of GnRH neurons in Sema3g-deficient mouse heads at 
E14.5, which is explained by a significant reduction of GnRH neurons reaching the FB (* p=0.017, ** p=0.004; 
n=3 for each group, two-sided unpaired Student’s t test). (C) ISH on sagittal histological sections of wild-type 
and Sema3g-/- embryos at E14.5 revealed a mild delay in Pit-1 lineage specification in knockout embryos 
compared to wild-types (black arrowheads). A modest reduction in α-GSU and Pomc1 mRNA levels is also 
detected in Sema3g-/- embryos (black arrowheads). 
Abbreviations: OB, olfactory bulb; OE, olfactory epithelium; VNO, vomeronasal organ; NFJ, nasal forebrain 
junction; MPOA, medial preoptic area; FB, forebrain; AL, anterior lobe; PL, posterior lobe; MZ, marginal zone; 
α-GSU, alpha-subunit glycoprotein; Pit-1, pituitary-specific positive transcription factor 1; Pomc1, pro-
opiomelanocortin 1. Scale bars: 200 μm. 
 
Figure 4. Sema3g loss does not impair the adult HPG axis.  
(A) Coronal sections of adult hypothalamus (P80) of the indicated genotypes at the level of the MPOA (upper 
panels) and at the level of the ME (lower panels) were immunostained to identify GnRH-positive neurons and 
axons; examples of normally projecting neurons in the MPOA are indicated with black arrowheads. 
Innervation of ME was similar between wild-types and mutants. (B) Quantification (mean ± s.e.m.) of GnRH 
neuron numbers in the MPOA and ME innervation of Sema3g+/+ and Sema3g-/- P80 mice (MPOA p=0.315 and 
ME p=0.195; n=4 for each group, two-sided unpaired Student’s t test). (C) Immunohistochemistry stainings 
against hormone-producing cells in coronal sections from the pituitaries of the indicated genotypes revealed 
no differences in terminal differentiation of hormone producing cells between wild-types and mutants. (D) 
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Microtome sections of the indicated genotypes were stained with Hematoxylin and eosin (H&E) (upper 
panels), for the Sertoli cell marker Sox9 (middle panels) or for the Leydig cell marker Cyp17a1 (lower panels). 
No differences were observed between wild-types and mutants. Black and white arrowheads indicate 
examples of normally Sox9 and Cyp17a1 expressing cells, respectively. Nuclei were counterstained with DAPI. 
(E) Quantitative qPCR for Sox9 and Cyp17a1 revealed no changes in their expression levels between control 
and mutant testes (Cyp17a1 mean ± s.e.m.: Sema3g+/+ 0.9 ± 0.1; Sema3g-/- 0.8 ± 0.3, p=0.580; Sox9 mean ± 
s.e.m.: Sema3g+/+ 1.0 ± 0.03; Sema3g-/- 0.9 ± 0.2, p=0.482; n=3 for each group, two-sided unpaired Student’s 
t test). 
Abbreviations: MPOA, medial preoptic area; ME, median eminence; 3v, third ventricle; ACTH, 
adrenocorticotropic hormone, GH, growth hormone, LH, luteinising hormone, PRL, prolactin; TSH, thyroid-
stimulating hormone; AL, anterior lobe; IL, intermediate lobe; PL, posterior lobe. Scale bar: 200 µm (A, C), 
100 μm (D). 
 
Figure 5. Mutated SEMA3G alters PLXNA binding properties in silico, in vitro and ex vivo. 
(A) Interaction network (upper panels) and patch analysis (lower panels) of SEMA3G::PLXNA1 wild-type and 
mutated SEMA3GG166V::PLXNA1 complexes: Asp410 residue of PLXNA1 (grey ribbons) interacts with Arg167 
of both wild-type SEMA3G (yellow ribbons) and p.G166V mutant SEMA3G (orange ribbon). Backbone and 
side chains are shown in stick representation; atoms involved in ionic and hydrogen bonds are surrounded 
by blue and red shells, respectively. Wild-type complex. Mild polar and H-Bonding areas on PLXNA1 molecular 
surface are highlighted in steel blue and purple, respectively (lower panels). Positive charged patch is colored 
in solid blue and pointed out by arrows; in solid red and arrows is shown positive, unfavourable, ΔG of 
solvation contribution to the complex formation. (B,C) Transfected COS-7 cells express similar levels of wild-
type and mutated (SEMA3GG166V) AP-fused human SEMA3G, as revealed by immunofluorescence (B) and 
immunoblotting (C). WB analysis on conditioned media also showed that the p.G166V mutation did not alter 
protein secretion. (D) AP-binding assay on COS-7 cells expressing human PLXNA4 or PLXNA1 after incubation 
with CM containing AP-conjugated control, wild-type SEMA3G or mutated SEMA3G. The p.G166V mutation 
increased the binding affinity to PLXNA4 and PLXNA1, as shown by relative quantification of integrated 
density (SEMA3GG166V vs wild-type SEMA3G: 3.3±0.8 PLXNA4, *p=0.038; PLXNA1 5.6±1.0, **p=0.004; n=4 for 
wild-type SEMA3G; n=3 for SEMA3GG166V; two-sided unpaired Student’s t test. (E) Coronal sections of E14.5 
mouse heads at the nasal level (nose) or at the forebrain (brain) level were incubated with SEMA3A-AP ligand 
alone (left panels) or before pre-incubation with SEMA3GG166V-AP ligand (right panels). Arrowheads 
indicate areas where SEMA3A binds in the nose and in the brain. Delta symbols indicate areas of reduced 
SEMA3A binding when the tissue was pre-incubated with SEMA3GG166V. Scale bar: 50 µm (B-D), 200 µm 
(E).  
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Figure 6. Mutated SEMA3G protein affects GN11 cell behavior and response to SEMA3A. (A) RT-PCR analysis 
performed on mRNA extracted from GN11 cells showed the presence of specific transcripts 
for Nrp1, Nrp2, Plxna1-4 and the standard Gapdh with amplicons of 188, 260, 250, 485, 195, 295 and 189 bp, 
respectively (B) AP-binding assay on GN11 cells after incubation with CM containing equal amounts of CTRL, 
wild-type SEMA3G or mutated SEMA3G. The p.G166V mutation did not affect the binding of SEMA3G on 
GN11 cells (C) Chemotactic response of GN11 cells to wild-type and mutated SEMA3G CM in a Boyden’s 
chamber assay in the absence or presence of SEMA3A. Left graph: wild-type SEMA3G induced a significant 
increase in the chemomigration of GN11 cells compared to control-CM, whereas no statistically significant 
differences were observed between control-CM and SEMA3GG166V-CM (CTRL vs WT ** p=0.003; CTRL vs 
G166V p=0.251; WT vs G166V p=0.085; One-way ANOVA followed by Dunnett post-hoc test, n=7). Right 
graph: wild-type SEMA3A induced a significant decrease in the chemomigration of GN11 cells compared to 
control-CM; this effect was abolished only when GN11 cells were co-exposed to SEMA3GG166V-CM, but not to 
SEMA3G-CM (CTRL vs 3A * p=0.011; CTRL vs 3A+3G WT * p=0.011; CTRL vs 3A+3G G166V p=0.808; 3A vs 
3A+3G G166V * p=0.035; 3A+3G WT vs 3A+3G G166V * p=0.038; One-way ANOVA followed by Tukey post-
hoc test, n=3). (D) Representative immunoblots and relative quantification show decreased levels of pAKT, 
relative to total AKT, in serum-starved GN11 cells treated with mutated SEMA3G protein at each time point 
(WT vs MUT: * p=0.025 (5’), * p=0.011 (15’), ** p=0.002 (30’), *** p=0.0006 (60’), Two-way ANOVA followed 
by Tuckey post-hoc test). (E) Evaluation of GN11 proliferation by PHH3 immunostaining after 24h incubation 
with wild-type and mutated SEMA3G CM. Mutated SEMA3G failed to promote cell proliferation compared 
to wild-type SEMA3G (** p=0.0011, control CM vs wild-type SEMA3G; p=0.294, control CM vs SEMA3GG166V; 
*** p=0.0003, wild-type SEMA3G vs SEMA3GG166V; One-way ANOVA followed by Tuckey post-hoc test). Data 
reported in C are shown as relative fold-change ± s.e.m. of n=7 independent experiments. Data reported in 
D and E are shown as mean ± s.e.m. of n=3 independent experiments. Scale bars: 100 µm (B, E).  
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Supplementary figures and tables 
 
Suppl. figure 1. 
 
 
Suppl. Figure 1. Riboprobe for Sema3g is specific. ISH reactions on coronal E14.5 mouse sections at the level 
of the nose with sense probes Sema3g revealed absence of signal. Abbreviation: OE, olfactory epithelium; 
VNO, vomeronasal organ. Scale bar: 500 µm. 
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Suppl. figure 2.  
 
 
Suppl. figure 2. Sema3g mRNA expression during GnRH neuron development. Adjacent coronal sections of 
mouse heads at the indicated developmental stages were RNA-labelled for GnRH or Sema3g; black 
arrowheads indicate examples of migrating GnRH neurons and of Sema3g+ cells.  
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Suppl. figure 3. 
 
 
Suppl. figure 3. Forebrain cell death via apoptosis, nasal axonal and vascular patterning are not affected in 
the Sema3g-null embryos.  
(A) Adjacent sagittal sections of E14.5 mouse heads of the indicated genotypes were immunolabelled for 
GnRH or activated caspase-3 to reveal GnRH neurons and apoptotic cells, respectively. High magnification 
areas indicated with white boxes are shown alongside. Black arrowheads indicate examples of GnRH neurons, 
while lack of apoptotic cells in the FB of wild-types and mutants is indicated with '. As positive control, 
sagittal sections of wild-type and Sema3g-null embryo heads at E14.5 were immunolabelled for activated 
caspase 3 to reveal apoptotic cells at the level of the tongue and of the salivary glands (SG) (right panels).  
(B-C) Normal nasal axon and blood vessel patterning in Sema3g-null mutants. Coronal sections of E14.5 
mouse heads of the indicated genotypes at the level of the nose were labelled with the blood vessel marker 
IB4 (B) or immunolabelled for peripherin (C). Nuclei were counterstained with DAPI. White arrowheads 
indicate examples of normal axonal branches projecting to the OB. Abbreviations: OB, olfactory bulb; OE, 
olfactory epithelium. Scale bars: 200 µm (A, low magnification), 100 µm (A, high magnification) 
150 μm (B–C), 50 μm (higher-magnification images of boxed areas in C). 
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Suppl. figure 4. 
 
Suppl. figure 4. Pituitary vascular structure is not affected in the absence of Sema3g. Immunohistochemical 
analysis with vasculature markers Endomucin and Pecam on sagittal sections of control (A-D) and Sema3g-/- 
(E-H) mouse E14.5 embryos. (B) and (F) are the enlarged images of the boxed areas in (A) and (E), whereas 
(D) and (H) are the magnified images of (C) and (G), respectively. Embryos lacking Sema3g gene (E-H) show 
no abnormalities in the vascular architecture of the pituitary gland when compared to the stage-matched 
controls (A-D). Abbreviations: AL, anterior lobe; PL, posterior lobe. Scale bars: 200 µm (A,C,E,G), 100 µm 
(B,D,F,H). 
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Suppl. figure 5.  
 
 
 
Suppl. figure 5. Homology model of SEMA3G::PLXNA1 complex.  
The three-dimensional structures of human SEMA3G and PLXNA1 in complex are represented as yellow and 
grey ribbons, respectively. 
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Suppl. Table 1. Protein contact analysis of the wild-type and mutated SEMA3G; the energetic contribution of 
each single bond type to the interaction energy is reported. 
 
PLXNA1 SEMA3G 
Energy 
contribution 
SEMA3G WT 
(kcal/mol) 
Energy 
contribution 
SEMA3G G166V 
(kcal/mol) 
Interaction type 
Asp410 Lys108 -1,597 -1,399 ionic 
Asp410 
Asp410 
Asp410 
Arg167 
Arg167 
Arg167 
-6,575 
-1,722 
-6,200 
-2,343 
- 
- 
ionic 
ionic 
hbond 
Leu389 Arg198 -5,000 -5,500 hbond 
Lys391 Arg198 -3,400 -9,000 hbond 
Glu223 Ala211 -4,900 -5,300 hbond 
Asp234 Asp217 -2,700 -4,200 hbond 
Asp234 
Asp234 
Gln218 
Gln218 
-6,400 
-6,200 
-6,100 
-6,400 
hbond 
hbond 
Lys391 
Lys391 
Asp223 
Asp223 
-7,354 
-8,900 
-7,332 
-8,900 
ionic 
hbond 
Lys238 
Lys238 
Lys238 
Asp255 
Asp255 
Asp255 
-7,170 
- 
-13,600 
-6,934 
-1,185 
-15,200 
ionic 
ionic 
hbond 
Lys156 
Lys156 
Gln277 
Gln277 
-3,900 
-3,200 
-0.900 
-10,600 
hbond 
hbond 
Tyr96 
Tyr96 
Arg278 
Arg278 
-3,200 
-5,500 
-3,500 
-5,800 
hbond 
hbond 
Tyr197 Arg278 -0.600 - hbond 
Glu223 Asn282 -7,200 -7,100 hbond 
Glu196 
Glu196 
Glu196 
Glu196 
Glu196 
Glu196 
Glu196 
Arg409 
Arg409 
Arg409 
Arg409 
Arg409 
Arg409 
Arg409 
-9,400 
-4,600 
- 
-6,577 
-3,469 
-1,998 
-6,563 
-9,100 
-0.800 
-4,600 
-6,225 
-4,327 
-1,367 
-6,844 
hbond 
hbond 
hbond 
ionic 
ionic 
ionic 
ionic 
TOTAL  -137,325 -139,256  
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